Quent Capital LLC Sells 223 Shares of Danaher Corporation $DHR

Quent Capital LLC lessened its holdings in shares of Danaher Corporation (NYSE:DHR) by 8.4% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,418 shares of the conglomerate’s stock after selling 223 shares during the quarter. Quent Capital LLC’s holdings in Danaher were worth $478,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. 111 Capital lifted its position in Danaher by 81.3% during the second quarter. 111 Capital now owns 5,908 shares of the conglomerate’s stock valued at $1,167,000 after purchasing an additional 2,649 shares during the last quarter. Ameriflex Group Inc. lifted its position in Danaher by 95.8% during the second quarter. Ameriflex Group Inc. now owns 374 shares of the conglomerate’s stock valued at $75,000 after purchasing an additional 183 shares during the last quarter. Franklin Street Advisors Inc. NC lifted its position in Danaher by 39.4% during the second quarter. Franklin Street Advisors Inc. NC now owns 2,886 shares of the conglomerate’s stock valued at $570,000 after purchasing an additional 815 shares during the last quarter. Barrett & Company Inc. lifted its position in Danaher by 96.2% during the second quarter. Barrett & Company Inc. now owns 520 shares of the conglomerate’s stock valued at $103,000 after purchasing an additional 255 shares during the last quarter. Finally, Phraction Management LLC lifted its position in Danaher by 21.3% during the second quarter. Phraction Management LLC now owns 47,182 shares of the conglomerate’s stock valued at $9,320,000 after purchasing an additional 8,280 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Up 2.2%

Shares of NYSE DHR opened at $215.05 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.41. The firm’s fifty day moving average is $200.19 and its 200 day moving average is $197.33. The company has a market cap of $153.98 billion, a price-to-earnings ratio of 45.75, a PEG ratio of 3.06 and a beta of 0.77.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same period in the previous year, the firm earned $1.72 earnings per share. The firm’s revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher’s payout ratio is presently 27.23%.

Analysts Set New Price Targets

Several research firms have commented on DHR. Evercore ISI decreased their price target on shares of Danaher from $230.00 to $226.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 8th. Wells Fargo & Company decreased their price target on shares of Danaher from $210.00 to $205.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 23rd. Robert W. Baird lifted their price target on shares of Danaher from $225.00 to $226.00 and gave the stock an “outperform” rating in a research note on Friday, July 18th. Royal Bank Of Canada set a $241.00 price target on shares of Danaher in a research note on Tuesday, September 2nd. Finally, Barclays reissued an “overweight” rating and set a $225.00 price target (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Seventeen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $245.91.

Insider Transactions at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.